Unknown

Dataset Information

0

Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.


ABSTRACT: The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents-obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol-are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.

SUBMITTER: Jeong SW 

PROVIDER: S-EPMC7643594 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.

Jeong Soung Won SW  

Diabetes & metabolism journal 20201021 5


The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents-obetichol  ...[more]

Similar Datasets

| S-EPMC10446130 | biostudies-literature
| S-EPMC6728526 | biostudies-literature
| S-EPMC4491606 | biostudies-literature
2011-01-05 | E-GEOD-26225 | biostudies-arrayexpress
| S-EPMC6977016 | biostudies-literature
| S-EPMC8237139 | biostudies-literature
| S-EPMC7460697 | biostudies-literature
| S-EPMC4482455 | biostudies-literature
| S-EPMC3278533 | biostudies-literature
| S-EPMC5401764 | biostudies-literature